Total
0
Shares
Medibio (ASX:MEB) - Board member, Michael Phelps
Board member, Michael Phelps
Sourced: Medibio
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Pioneering mental health tech company Medibio (MEB) has successfully completed a pilot program for British food and catering company Compass
  • Medibio’s novel mental health and wellbeing program, ilumen, aims to aid in the early detection and screening of mental health conditions
  • Medibio presented the ilumen pilot results to Compass management, providing valuable insights into employee wellbeing
  • Importantly, the program was able to identify lost productivity hours, providing Compass with a dollar value of potential losses
  • Medibio confidentially contacted at-risk employees with personalised emails recommending they seek help for their mental health
  • The two companies are now in discussions regarding the ongoing implementation of ilumen
  • Medibio is still trading at its opening price of 0.8 cents a share

Pioneering mental health tech company Medibio (MEB) has successfully completed a pilot program for British food and catering company Compass.

The program

Medibio’s novel mental health and wellbeing program, ilumen, aims to use objective measures to aid in the early detection and screening of mental health conditions. This program was the fourth and final pilot study conducted in conjunction with the Compass Group.

Medibio reports excellent participation rates across the four studies, with 60 to 71 per cent of the target workforce volunteering for the program. The company believes these pilot programs have provided valuable insights for discussions with the Compass Group regarding an ongoing relationship for ilumen.

The results

Medibio presented the ilumen pilot results to Compass management, providing valuable insights into employee wellbeing. The results rendered anonymous data – protecting participants’ privacy – on key mental health metrics which could be filtered by location, department and demographic factors.

Importantly, the program was able to identify lost productivity hours, providing Compass with a dollar value of potential losses due to mental health issues.

Even more importantly, the ilumen program was able to identify high-risk Compass employees. Those staff were not identified to Compass management. Instead, Medibio sent those employees a confidential, personalised email recommending they see a doctor, contact their Employee Assistance Program or access other assistance. This discreet dealing with at-risk employees is a key part of the ilumen program, and of mental health care generally.

Medibio believes it has delivered important mental health care, information and advice to Compass employees and management. The two companies are now in discussions regarding the ongoing implementation of ilumen.

Medibio had a slight early bump, but has settled back to its opening price of 0.8 cents a share as at 2:55 pm AEST.

MEB by the numbers
More From The Market Herald
ResApp Health (ASX:RAP) - CEO & Managing Director, Dr Tony Keating

" ResApp (ASX:RAP) secures new licences in Q3 amid revenue slump

ResApp Health (RAP) has released its quarterly activities report for the three months to the end of September 2021.

" Incannex Healthcare (ASX:IHL) lands ethics approval for psychedelic-based anxiety treatment trial

Incannex Healthcare (IHL) has spiked on the ASX today after landing important regulatory approvals to trial a psychedelic-based treatment for severe anxiety.

" Rhinomed (ASX:RNO) receives ethics approval for Rhinoswab trial

Wearable nasal and respiratory company Rhinomed (RNO) has received ethics approval to undertake a clinical trial of Rhinoswab at St Vincents Hospital in
Security Matters (ASX:SMX) - CEO, Haggai Alon

" Security Matters (ASX:SMX) increases customer receipts in Q3

Security Matters (SMX) has delivered a recap of its quarterly activities during the three months ending September 30 2021.